SPOTLIGHT: NOXXON, Pfizer ink pact
Pfizer has licensed an experimental obesity therapy from Germany's NOXXON Pharma in a multi-year pact that includes a direct equity investment, an up front payment and milestones. NOXXON will use its Spiegelmer technology--mirror-image RNA molecules not found in nature--to identify new candidates. Release
Comments